On June 7, 2023, Todd Foley notified Entrada Therapeutics, Inc. (the “Company”) of his resignation as a member of the Company’s Board of Directors (the “Board”), effective as of June 7, 2023.
Key facts
Extracted from this filing and checked against the source text.
Executive changeSEC 8-K Item 5.02confidence 0.95
Todd Foley resigned as member of the Board of Directors at Entrada Therapeutics, Inc..
Action
resigned
Role
member of the Board of Directors
Exact text from the filing
On June 7, 2023, Todd Foley notified Entrada Therapeutics, Inc. (the “Company”) of his resignation as a member of the Company’s Board of Directors (the “Board”), effective as of June 7, 2023.
Entrada Therapeutics, Inc. shareholders approved Election of two Class II directors at the 2023-06-08 meeting.
Proposal
director election
Outcome
passed
Meeting
2023-06-08
Exact text from the filing
Proposal No. 1 Peter S. Kim, Ph.D. and Bernhardt Zeiher, M.D. were duly elected to the Company’s Board as Class II directors. The results of the election were as follows: CLASS II DIRECTOR NOMINEE FOR WITHHELD BROKER NON-VOTES Peter S. Kim, Ph.D. 24,512,848 245,047 1,876,971 Bernhardt Zeiher, M.D. 24,696,429 61,466 1,876,971
Entrada Therapeutics, Inc. shareholders approved Ratification of appointment of Ernst & Young LLP as independent registered public accounting firm at the 2023-06-08 meeting.
Proposal
auditor ratification
Outcome
passed
Meeting
2023-06-08
Exact text from the filing
Proposal No. 2 The appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 was ratified. The results of the ratification were as follows: FOR AGAINST ABSTAIN 26,634,250 606 10
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.